Blog
How to select sensitive outcome measures in pro-cognitive drug trials for schizophrenia
The outcome measure selected for a pro-cognitive drug trial in schizophrenia must be sensitive enough to detect potentially subtle changes in cognition.
Evolocumab Phase 3 Cognitive Function Study Results Published in the New England Journal of Medicine
Cambridge Cognition and Amgen announce that the New England Journal of Medicine (NEJM) published results from the evolocumab cognitive function trial, which was conducted in a subset of patients enrolled in the randomized, placebo-controlled evolocumab cardiovascular outcomes study.
web-based testing,
wearables,
voice,
virtual clinical trials,
technology,
swm,
subjective measures,
stigma,
social cognition,
smartphones,
sleep,
schizophrenia research,
schizophrenia,
safety,
rvp,
rti,
research funding,
research,
remote testing,
regulations,
recruitment,
rare disease,
prodromal,
pro-cognitive,
prm,
press release,
presenteeism,
precision psychiatry,
pre-clinical,
poster,
personalised medicine,
patient-centric,
patient recruitment,
parkinson's disease,
pal,
paired associates learning,
ots,
occupational health,
normative data,
neuroscience,
near-patient testing,
multiple sclerosis,
mts,
ms,
modelling,
mental wellbeing,
mdd,
mci,
major depression,
machine learning,
life at cambridge cognition,
high-frequency testing,
healthcare,
grant,
funding,
fatigue,
ert,
epidemiology,
ebt,
early career researchers,
early alzheimer's disease,
drug development,
dms,
digital tools,
digital health,
depression,
dementia,
covid-19,
cognitive testing,
cognitive science,
cognitive safety,
cognitive impairment,
cognitive function,
cognitive dysfunction,
cognitive deficits,
cognitive biomarkers,
cognitive assessment,
cognition kit,
cognition,
cns summit,
clinical trials,
clinical trial,
cias,
chronic illness,
chronic health conditions,
cgt,
cantab testimonial,
cantab research grant,
cantab,
cambridge cognition careers,
cambridge cognition,
brain health,
biomarkers,
automatic speech recognition,
autism,
attention,
asr,
alzheimer's disease,
academic,
absenteeism,
